Drug Information

Drug (ID: DG00406) and It's Reported Resistant Information

• Name: Sulfathiazole
• Synonyms: Sulfathiazole; 72-14-0; Sulphathiazole; Sulfathiazol; 2-Sulfanilamidothiazole; Sulfanilamidothiazole; Thiazamide; Norsulfasol; Norsulfazole; 2-Sulfonamidothiazole; 4-Amino-N-(thiazol-2-yl)benzenesulfonamide; 2-(Sulfanilylamino)thiazole; Neostrepsan; Sulfocerol; Thiozamide; Sulzol; 2-Sulfanilamidothiazol; 2-(p-Aminobenzenesulfonamido)thiazole; Azoquimiol; Azoseptale; Norsulfazol; Poliseptil; Sanotiazol; Sulfathiazolum; Sulfatiazol; Thiacoccine; Thiasulfol; Wintrazole; Cerazole; Chemosept; Cibazol; Eleudron; Estafilol; Planomide; Septozol; Duatok; Dulana; N(1)-2-Thiazolylsulfanilamide; Coco-Thiazole; Formosulfathiazole; Streptosilthiazole; Sulfamul; 2-(p-Aminobenzenesulphonamido)thiazole; Usaf sn-9; 4-Amino-N-2-thiazolylbenzenesulfonamide; Cerazol (suspension); Ciba 3714; 4-Amino-N-(1,3-thiazol-2-yl)benzenesulfonamide; N1-(2-Thiazolyl)sulfanilamide; Benzenesulfonamide, 4-amino-N-2-thiazolyl-; 4-Amino-N-(1,3-Thiazol-2-Yl)Benzene-1-Sulfonamide; 4-amino-N-1,3-thiazol-2-ylbenzenesulfonamide; M&B 760; RP 2090; UNII-Y7FKS2XWQH; 4-Amino-N-thiazol-2-yl-benzenesulfonamide; 2090 R.P.; M+B 760; CHEBI:9337; Sulfanilamide, N1-2-thiazolyl-; Y7FKS2XWQH; Sodium sulfathiazole; CHEMBL437; N'-(2-Thiazolyl)sulfanilamide; N(sup1)-(2-Thiazolyl)sulfanilamide; MFCD00005319; NSC-31812; NSC683531; Sulfanilamide, N(sup1)-2-thiazolyl-; NSC-683531; CAS-72-14-0; NCGC00016309-02; NCGC00016309-06; Norsulfazolum; 4-Amino-N-(2-thiazolyl)benzenesulfonamide; DSSTox_CID_6068; DSSTox_RID_78004; DSSTox_GSID_26068; Solfatiazolo [DCIT]; Caswell No. 809B; Solfatiazolo; Sulfathiazol [INN-French]; Sulfatiazol [INN-Spanish]; N1-2-Thiazolylsulfanilamide; Sulfathiazolum [INN-Latin]; CCRIS 765; 2090 rp; 2-Sulfanilamidothiazol [German]; HSDB 4380; N(sup 1)-2-Thiazolylsulfanilamide; SR-05000001722; Sulfanilamide, N(1)-2-thiazolyl-; EINECS 200-771-5; NSC 31812; EPA Pesticide Chemical Code 077903; NSC 683531; Sulfanilamide, N(sup 1)-2-thiazolyl-; sulfthiazole; Enterobiocine; Sulfavitina; Cerazol; AI3-01050; Sulfathiazole [USP:INN:BAN]; 2-Sulfathiazole; YTZ; Prestwick_430; Sulfathiazole-13C6; Spectrum_001000; Prestwick0_000016; Prestwick1_000016; Prestwick2_000016; Prestwick3_000016; Spectrum2_000841; Spectrum3_001729; Spectrum4_000348; Spectrum5_001441; Sulfathiazole (USP/INN); N-2-Thiazolylsulfanilamide; Epitope ID:122234; Cambridge id 5251400; cid_5340; Oprea1_105970; Oprea1_297844; SCHEMBL94165; Triple sulfa (sulfathiazole); BSPBio_000051; BSPBio_003378; KBioGR_000755; KBioSS_001480; [(4-Aminophenyl)sulfonyl]-1,3-thiazol-2-ylamine; MLS002154174; N-1-2-Thiazolylsulfanilamide; DivK1c_000560; SPECTRUM1500553; Sulfathiazole-d4(benzene-d4); SPBio_000821; SPBio_001972; BPBio1_000057; WLN: T5N CSJ BMSWR DZ; DTXSID8026068; HMS501L22; KBio1_000560; KBio2_001480; KBio2_004048; KBio2_006616; KBio3_002598; N(sup1)-2-Thiazolylsulfanilamide; NINDS_000560; HMS1568C13; HMS1921C07; HMS2092K09; HMS2095C13; HMS2259A13; HMS3652A03; HMS3712C13; Pharmakon1600-01500553; ZINC121458; AMY33440; HY-B0507; NSC31812; SULFATHIAZOLE (TRIPLE SULFA); Tox21_110363; Tox21_202243; Tox21_303238; BDBM50027796; CCG-40296; NSC757331; s3116; STK043870; 2-(4-Aminobenzenesulfonamido)thiazole; AKOS000108630; Tox21_110363_1; DB06147; MCULE-1370710137; NSC-757331; SDCCGMLS-0065585.P001; IDI1_000560; NCGC00016309-01; NCGC00016309-03; NCGC00016309-04; NCGC00016309-05; NCGC00016309-07; NCGC00016309-08; NCGC00016309-09; NCGC00016309-10; NCGC00016309-14; NCGC00091133-01; NCGC00091133-02; NCGC00091133-03; NCGC00091133-04; NCGC00257187-01; NCGC00259792-01; Sulfanilamide, N1-2-thiazolyl- (8CI); AC-12783; DS-17245; K225; NCI60_002730; SMR000017368; Pyridine,2-(chloromethyl)-3,4-dimethoxy-; SBI-0051527.P004; Sulfanilamide, N1-4-thiazolin-2-ylidene-; DB-055610; 4-amino-N-(thiazol-2-yl)-benzenesulfonamide; AB00052102; BB 0245015; FT-0631310; Sulfathiazole 100 microg/mL in Acetonitrile; SW149625-4; 4-[(1,3-Thiazol-2-yl)aminosulfonyl]aniline; Sulfathiazole, analytical standard, >=98.0%; 9610-EP2295053A1; 9610-EP2308872A1; 9610-EP2316829A1; D01047; D70411; AB00052102_14; AB00052102_15; Q408427; Sulfathiazole, VETRANAL(TM), analytical standard; 4-Amino-N-(1,3-thiazol-2-yl)benzenesulfonamide #; Q-201765; SR-05000001722-1; SR-05000001722-3; Sulfathiazole, Antibiotic for Culture Media Use Only; BRD-K14705039-001-05-7; BRD-K14705039-001-08-1; F1443-4816; Sulfathiazole, European Pharmacopoeia (EP) Reference Standard; Sulfathiazole, United States Pharmacopeia (USP) Reference Standard
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Escherichia coli intestinal infection [ICD-11: 1A03]; [1]
• Formula: C9H9N3O2S2
• IsoSMILES: C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2
• InChI: 1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)
• InChIKey: JNMRHUJNCSQMMB-UHFFFAOYSA-N
• PubChem CID: 5340
• DrugBank ID: DB06147

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Escherichia coli intestinal infection [ICD-11: 1A03]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Dihydrofolate reductase (DHFR) [1]

• Molecule Alteration: Missense mutation; p.P64S
• Resistant Disease: Escherichia coli infection [ICD-11: 1A03.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Escherichia coli strain BN102; 562
• In Vitro Model: Escherichia coli strain BN122; 562
• In Vitro Model: Escherichia coli strain BN123; 562
• Experiment for Molecule Alteration: Direct PCR sequencing assay
• Experiment for Drug Resistance: MIC assay
• Mechanism Description: Escherichia coli BN122 and BN123 folP sequences were identical to one another, but they contained a single difference from the wild-type nucleotide sequence. The difference was a C-to-T transition at nucleotide 184, resulting in a Pro-to-Ser substitution at amino acid 64. The sequence of this region of folP aligned with DHPS sequences from a variety of additional sources. Pro64 lies very close to the active site of DHPS, adjacent to Arg63, whose side chain bonds in a hydrogen bond with an oxygen of the sulfanilamide inhibitor. Substitution of Pro64 by Ser is likely to alter the local structure of the peptide, in turn altering the ability of Arg63 to contact the inhibitor.

References

• Ref 1: Characterization of mutations contributing to sulfathiazole resistance in Escherichia coli. Antimicrob Agents Chemother. 1998 Jan;42(1):88-93. doi: 10.1128/AAC.42.1.88.